# Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

> **NCT00720109** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 63 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

## Interventions

- **DRUG:** Asparaginase
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dasatinib
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Hydrocortisone Sodium Succinate
- **DRUG:** Ifosfamide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Methylprednisolone
- **DRUG:** Pegaspargase
- **DRUG:** Prednisone
- **RADIATION:** Radiation Therapy
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT00720109
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-14
- **Primary completion:** 2014-12-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720109, "Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00720109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*